PAPADOPOULOS STELIOS 4
4 · Ovid Therapeutics Inc. · Filed Apr 9, 2026
Research Summary
AI-generated summary of this filing
Ovid (OVID) Director Stelios Papadopoulos Receives RSU Award
What Happened
Stelios Papadopoulos, a director of Ovid Therapeutics, was granted 17,578 restricted stock units (RSUs) on April 7, 2026. The award is valued at $45,000 based on a grant price of $2.56 per share. The RSUs were issued in lieu of his annual cash retainer for board service.
Key Details
- Transaction type: Award/Grant (code A) on 2026-04-07; Form 4 filed 2026-04-09 (appears timely).
- Amount: 17,578 RSUs at $2.56 per share, total value $45,000.
- Vesting: 25% vested upon grant (approximately 4,395 RSUs) and the remaining 75% vest 25% on each of June 30, 2026, Sept 30, 2026, and Dec 31, 2026, subject to continuous service (per footnote F1).
- Shares owned after transaction: Not specified in this filing.
- Other notes: Award issued under the company’s Non-Employee Director Compensation Policy in lieu of cash. No tax withholding, sale, or 10b5-1 plan mentioned.
Context
Director RSU grants are a common form of board compensation and do not necessarily indicate the director’s view on the company’s stock. Unlike open-market purchases or insider sales, awards primarily reflect routine compensation practices rather than a direct market signal.
Insider Transaction Report
Form 4
PAPADOPOULOS STELIOS
Director
Transactions
- Award
Common Stock
[F1]2026-04-07$2.56/sh+17,578$45,000→ 217,578 total
Footnotes (1)
- [F1]Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.
Signature
/s/ Jeffrey Rona, Attorney-in-Fact|2026-04-09